Key result
Cardiac CT contrast carries low complication rates, with unsatisfactory enhancement occurring in ~4% of cases.
Observational (n=1,842)
Yes
Answers are grounded in this paper and cite their sources.
Observational study reveals low adverse reaction rates and robust vascular enhancement with intravenous contrast media in cardiac computed tomography, highlighting strong clinical safety.
PURPOSE: The Italian Registry of Contrast Material use in Cardiac Computed Tomography (iRCM-CCT) is a multicenter, multivendor, observational study on the use of contrast media (CM) in patients undergoing cardiac computed tomography (CCT). The aim of iRCM-CCT is to assess image quality and safety profile of intravenous CM compounds. MATERIALS AND METHODS: iRCM-CCT enrolled 1842 consecutive patients undergoing CCT (≥50 per site) at 20 cluster sites with the indication of suspected coronary artery disease. Demographic characteristics, CCT, and CM protocols, clinical indications, safety markers, radiation dose reports, qualitative (ie, poor vascular enhancement) and quantitative (ie, HU attenuation values) image parameters were recorded. A centralized coordinating center collected and assessed all image parameters. RESULTS: The cohort included 891 men and 951 women (age: 63±14 y, body mass index: 26±4 kg/m2) studied with ≥64 detector rows computed tomography scanners and different iodinated intravenous CM protocols and compounds (iodixanol, iopamidol, iohexol, iobitridol, iopromide, and iomeprol). The following vascular attenuation was reported: 504±147 HU in the aorta, 451±146 HU in the right coronary artery, 474±146 HU in the left main, 451±146 HU in the left anterior descending artery, and 441±149 HU in the circumflex artery. In 4% of cases the image quality was not satisfactory due to poor enhancement. The following adverse reactions to CM were recorded: 6 (0.3%) extravasations and 17 (0.9%) reactions (11 mild, 4 moderate, 2 severe). CONCLUSIONS: In a multicenter registry on CM use during CCT the prevalence of CM-related adverse reactions was very low. The appropriate use of CM is a major determinant of image quality.
No takes yet. Share an insight, caveat, or question.
Grutta et al. (2022) conducted an observational in Suspected coronary artery disease (n=1,842). Iodinated intravenous contrast media (iodixanol, iopamidol, iohexol, iobitridol, iopromide, iomeprol) was evaluated on Image quality (unsatisfactory enhancement) and contrast media-related adverse reactions. Iodinated intravenous contrast media use during cardiac CT resulted in low rates of adverse reactions and unsatisfactory enhancement in 4% of cases.
Synapse has enriched 10 related papers. Consider them for comparative context: